JGHF Okuda State-of-the-Art Lecture – Selection and Recipients
background
Professor Kunio Okuda was one of the pioneers of hepatology and a great supporter of gastroenterology and the study of liver disease in the Asia Pacific region. In the course of a career that flourished for more than 50 years since publishing his first paper he made an extraordinary number of contributions to the field. He published many books and innumerable articles and reviews. He also trained and influenced two generations of liver specialists from throughout the Asia Pacific region as well as from his native Japan.
Among his accomplishments – which included receiving many Japanese and international distinctions, prizes and awards – he was perhaps most proud of having been a co-founder of the Asian Pacific Association for the Study of the Liver (APASL). He was also an inaugural Editor of the Journal of Gastroenterology (Editor-in-Chief until the time of his death in February 2003) and a founding Trustee of the JGHFoundation. With his permission the JGH State-of-the-Art Lecture was renamed the JGHF Okuda Lecture in September 2002.
First JGHF Okuda Lecture
The first JGHF Okuda Lecture was delivered at the APASL meeting in Taipei in 2002, in the presence of Professor Okuda, by Professor Geoffrey Farrell from Sydney, Australia and was titled ‘NASH. What is it and why is it important in the Asia Pacific Region.
SELECTIOn
- The APDW Federation nominates three (3) potential lecturers and appropriate topics.
- The potential nominees should come from more than one country within Asia Pacific region.
- The JGHFoundation will make the final decision on the selection of the lecturer in the year preceding the lecture.
- The APDW Federation advises the APDW Local Organising Committee who notifies the selected lecturer.
Funding
The funding package is to assist in covering the following expenses:
- Return airfares economy for national sector and business class for international sector (or two economy class airfares for the full trip to equivalent cost) between home city and the venue for the APDW meeting.
- Accommodation for the duration of APDW.
- Honorarium of US$2,000 for submission of manuscript at the time of the meeting for publication in the Journal of Gastroenterology and Hepatology (JGH).
- All travel and accommodation arrangements will be made by the APDW organisers.
- The selected Lecturer must ensure that both a manuscript and all relevant receipts are provided to the APDW organisers to receive reimbursement and payment.
Manuscript
The JGHF Okuda State of the Art Lecturer is required to submit a manuscript at the time of the meeting that will cover the content of his/her lecture. The manuscript should be structured as a review article between 3,000-5,000 words and between 3-8 tables and figures. It is expected that this will be a detailed and learned exposé of the topic concerned, and will also emphasise practical points for clinicians and investigators. For information on JGH style guidelines please see the Wiley-Blackwell House Style Guide
award recipients
| Year | Recipient | City | Topic |
|---|---|---|---|
| 2024 | Seng Gee Lim | Singapore | Lessons learnt from Hepatitis B elimination programs |
| 2023 | Pei-Jer Chen | Taiwan | Hepatitis B: What Remains To Be Solved |
| 2022 | Ji-dong Jia | Beijing | Novel Diagnosis and Therapy for Autoimmune Liver Diseases |
| 2021 | Kazuichi Okazaki | Osaka | Current Perspectives on IgG4-Related Disease in Hepato-Gastroenterology |
| 2020 | Not presented due to COVID-19 | ||
| 2019 | Tooru Shimosegawa | Sendai | Clinical features and diagnosis of early-stage pancreatic cancer |
| 2018 | Henry Chan | Hong Kong | Challenges of Hepatitis B in the Era of Antiviral Therapy |
| 2017 | Ching Lung Lai | Hong Kong | Chronic Hepatitis B: HBsAg seroclearance, cccDNA and Treatment under Trial |
| 2016 | John Windsor | Auckland | Novel strategies for treating severe acute pancreatitis |
| 2015 | Edward Gane | Auckland | Advances in HCV Therapy- Towards a Global HCV Elimination |
| 2014 | Stephen Locarnini | Melbourne | New Therapeutic Targets Against Hepatitis B Virus: The Need for Molecular and Immune Based Treatments |
| 2013 | Fu-sheng Wang | Beijing | Immune disorders lead to liver damage and influence antiviral efficacy in patients with chronic HBV infection |
| 2012 | Jia-Horng Kao | Taipei | Risk stratification for HBV-related HCC, Jia Horng Kao, Taipei |
| 2011 | Mashashi Mizokami | Chiba | Optimising Treatment for Chronic Hepatitis C – incorporating molecular medicine into clinical practice |
| 2010 | Anna Suk-Fong Lok | Michigan | Does antiviral therapy for hep B & C prevent HCC? |
| 2009 | Ding-Shinn Chen | Taipei | Towards Elimination and Eradication of Hepatitis B |
| 2008 | Masashi Mizokami | Nagoya | Management of hepatocellular carcinoma; From surveillance to molecular targeted therapy. |
| 2007 | No award made | ||
| 2006 | Malcolm Alison | London | Stem Cell Therapy in Liver Diseases |
| 2005 | Sung-Gyu Lee | Seoul | Asian Contribution to living donor liver transplantation |
| 2004 | Daiming Fan | Xian | A bird’s-eye view on gastric cancer research of the past 25 years |
| 2003 | Shiu-Kum Lam | Hong Kong | The role of cyclo-oxygenase (COX) in GI Diseases |
| 2002 | Yun-Fan Liaw | Taipei | Hepatitis flares and HBeAg seroconversion: Implications in anti-HBV |